title: Natural and synthetic cathelicidin peptides with anti-microbial and anti-biofilm activity against Staphylococcus aureus.
abstract: BACKGROUND
  Chronic, infected wounds typically contain multiple genera of bacteria, including Staphylococcus aureus, many of which are strong biofilm formers. Bacterial biofilms are thought to be a direct impediment to wound healing. New therapies that focus on a biofilm approach may improve the recovery and healing rate for infected wounds. In this study, cathelicidins and related short, synthetic peptides were tested for their anti-microbial effectiveness as well as their ability to inhibit the ability of S. aureus to form biofilms.
  
  
  RESULTS
  The helical human cathelicidin LL-37 was tested against S. aureus, and was found to exhibit effective anti-microbial, anti-attachment as well as anti-biofilm activity at concentrations in the low μg/ml range. The effect of peptide chirality and associated protease-resistance was explored through the use of an all-D amino acid peptide, D-LL-37, and in turn compared to scrambled LL-37. Helical cathelicidins have been identified in other animals such as the Chinese cobra, Naja atra (NA-CATH). We previously identified an 11-residue imperfectly repeated pattern (ATRA motif) within the sequence of NA-CATH. A series of short peptides (ATRA-1, -2, -1A), as well as a synthetic peptide, NA-CATH:ATRA1-ATRA1, were designed to explore the significance of the conserved residues within the ATRA motif for anti-microbial activity. The CD spectrum of NA-CATH and NA-CATH:ATRA1-ATRA1 revealed the structural properties of these peptides and suggested that helicity may factor into their anti-microbial and anti-biofilm activities.
  
  
  CONCLUSIONS
  The NA-CATH:ATRA1-ATRA1 peptide inhibits the production of biofilm by S. aureus in the presence of salt, exhibiting anti-biofilm activity at lower peptide concentrations than NA-CATH, LL-37 and D-LL-37; and demonstrates low cytoxicity against host cells but does not affect bacterial attachment. The peptides utilized in this anti-biofilm approach may provide templates for a new group of anti-microbials and potential future topical therapeutics for treating chronic wound infections.
authors: Department of Molecular and Microbiology, George Mason University, Manassas, VA 20110, USA.
authors: Scott N
authors: SN
authors: Dean
authors: Barney M
authors: BM
authors: Bishop
authors: Monique L
authors: ML
authors: van Hoek
references: J Immunol. 2009 Aug 15;183(4):2688-96
references: 19605696
references: Biochim Biophys Acta. 1998 Oct 23;1425(2):361-8
references: 9795251
references: J Immunol. 2010 Apr 1;184(7):3526-34
references: 20190140
references: Infect Immun. 2002 Nov;70(11):6339-45
references: 12379713
references: Chin Med J (Engl). 2007 Apr 20;120(8):708-13
references: 17517189
references: Wound Repair Regen. 2008 Jan-Feb;16(1):37-44
references: 18086294
references: J Immunol. 2005 Oct 1;175(7):4662-8
references: 16177113
references: Infect Immun. 2005 Aug;73(8):5241-4
references: 16041048
references: J Biol Chem. 1998 Jul 17;273(29):18586-93
references: 9660830
references: Microb Ecol. 2010 Apr;59(3):457-65
references: 19763680
references: J Wound Care. 2010 Feb;19(2):45-6, 48-50, 52-3
references: 20216488
references: Pharmacol Rev. 2003 Mar;55(1):27-55
references: 12615953
references: Med Microbiol Immunol. 2002 Oct;191(2):101-6
references: 12410349
references: J Invest Dermatol. 2003 Mar;120(3):379-89
references: 12603850
references: Biochem Biophys Res Commun. 2010 May 28;396(2):246-51
references: 20399752
references: Antimicrob Agents Chemother. 1998 Sep;42(9):2206-14
references: 9736536
references: Eur J Biochem. 2002 Feb;269(4):1181-9
references: 11856344
references: Proc Natl Acad Sci U S A. 1990 Jun;87(12):4761-5
references: 1693777
references: J Biol Chem. 2004 Apr 2;279(14):13896-901
references: 14718539
references: Curr Eye Res. 2005 May;30(5):385-94
references: 16020269
references: J Leukoc Biol. 2001 May;69(5):691-7
references: 11358975
references: Peptides. 2008 Oct;29(10):1685-91
references: 18620012
references: N Engl J Med. 1998 Aug 20;339(8):520-32
references: 9709046
references: Infect Immun. 2000 May;68(5):2748-55
references: 10768969
references: Peptides. 2003 Nov;24(11):1741-6
references: 15019205
references: Biochem Biophys Res Commun. 2010 Jun 11;396(4):825-30
references: 20438706
references: Int J Artif Organs. 2010 Sep;33(9):582-9
references: 20963725
references: Infect Immun. 2005 Oct;73(10):6771-81
references: 16177355
references: Lett Appl Microbiol. 2010 Feb;50(2):211-5
references: 20002576
references: APMIS. 2009 Jul;117(7):492-9
references: 19594489
references: PLoS One. 2008 Sep 16;3(9):e3217
references: 18795096
references: Antimicrob Agents Chemother. 2007 Nov;51(11):4125-32
references: 17785509
references: Semin Hematol. 1997 Oct;34(4):343-54
references: 9347585
references: J Biol Chem. 2008 Nov 7;283(45):30471-81
references: 18765670
references: Nat Rev Microbiol. 2005 Mar;3(3):238-50
references: 15703760
references: J Biol Chem. 2008 Nov 21;283(47):32637-43
references: 18818205
references: Clin Orthop Relat Res. 2005 Aug;(437):41-7
references: 16056024
references: JAMA. 2007 Oct 17;298(15):1763-71
references: 17940231
references: Microbiol Mol Biol Rev. 2009 Jun;73(2):310-47
references: 19487730
references: Appl Environ Microbiol. 2008 Jan;74(2):470-6
references: 18039822
references: J Antimicrob Chemother. 2008 Jun;61(6):1266-9
references: 18367458
references: J Immunol. 2003 Dec 15;171(12):6690-6
references: 14662872
references: Nature. 2002 Jan 24;415(6870):389-95
references: 11807545
references: J Appl Microbiol. 2011 Jan;110(1):229-38
references: 20961363
references: Biochem Biophys Res Commun. 2003 Sep 26;309(3):591-7
references: 12963031
references: Infect Immun. 2008 Sep;76(9):4176-82
references: 18591225
references: J Immunol Methods. 1997 Aug 7;206(1-2):53-9
references: 9328568